Sol-Gel Technologies (4SG) AI Stock Analysis

0 Followers

Sol-Gel Technologies

(Frankfurt:4SG)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue rebound and product economicsThe sharp 2025 revenue rebound and near-revenue-level gross profit indicate that approved products and commercial activity can generate attractive product economics. If the company sustains demand beyond the prior weak period, this foundation could support operating leverage and improve future earnings quality.

Negative Factors

Persistent losses and shrinking equityContinued net losses are eroding the equity base even though leverage remains low. Capital depletion reduces financial resilience, may constrain investment in the pipeline, and increases dependence on future operating improvement or external financing to sustain the business over time.

Sol-Gel Technologies (4SG) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 201.35M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -10.9
Beta (1Y): 1.56
Revenue Growth: -92.78%
EPS Growth: -242.05%
Country: Germany
Employees: 28
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Sol-Gel Technologies Business Overview & Revenue Model

Company Description

Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation techno...

Sol-Gel Technologies Risk Analysis

Sol-Gel Technologies disclosed 72 risk factors in its most recent earnings report. Sol-Gel Technologies reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.The third-party logistics providers we will rely on may be unable to warehouse, label and/or supply our products in a timely and efficient manner, which can adversely affect our relationship with our customers..Q4, 2020

2.The ongoing COVID-19 pandemic may adversely affect our business, revenues, results of operations and financial condition.Q4, 2020

Sol-Gel Technologies Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4SG against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRZN	53Neutral	$622.17M	-0.78	71.81%	―	192.12%	-100.54%
OVID	52Neutral	$546.83M	-6.83	-23.38%	―	-78.05%	63.85%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMDX	43Neutral	$80.83M	-1.63	271.76%	―	-60.77%	57.26%
MGX	43Neutral	$26.44M	-0.28	-63.65%	―	-59.84%	-5.97%
STTK	40Underperform	$493.94M	-9.51	-46.46%	―	-100.00%	50.26%

* Healthcare Sector Average

Performance Comparison

DE:4SG and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4SG	Sol-Gel Tech	52.50	26.10	98.86%
IMDX	Insight Molecular Diagnostics Inc.	2.47	-6.01	-70.87%
OVID	Ovid Therapeutics	2.80	1.48	112.12%
STTK	Shattuck Labs, Inc.	4.85	2.93	152.60%
SRZN	Surrozen, Inc.	32.64	19.70	152.24%
MGX	Metagenomi, Inc.	0.70	-1.16	-62.37%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sol-Gel Technologies AI Stock Analysis